A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer

Andrew M. Scott, Greg Wiseman, Sydney Welt, Alex Adjei, Fook Thean Lee, Wendie Hopkins, Chaitan R. Divgi, Lorelei H. Hanson, Paul Mitchell, Denise N. Gansen, Steven M. Larson, James N. Ingle, Eric W. Hoffman, Paul Tanswell, Gerd Ritter, Leonard S. Cohen, Peter Bette, Lisa Arvay, Andree Amelsberg, Dan VlockWolfgang J. Rettig, Lloyd J. Old

Research output: Contribution to journalArticlepeer-review

256 Scopus citations


Purpose: The purpose of this research was to determine the safety, immunogenicity, pharmacokinetics, biodistribution, and tumor uptake of repeat infusions of a complementarity-determining region grafted humanized antibody (sibrotuzumab) directed against human fibroblast activation protein (FAP). Experimental Design: A Phase I open-label dose escalation study was conducted in patients with cancers epidemiologically known to be FAP positive. Patients were entered into one of four dosage tiers of 5, 10, 25, or 50 mg/m2 sibrotuzumab, administered weekly for 12 weeks, with trace labeling with 8-10 mCi of 131I in weeks 1, 5, and 9. Results: A total of 26 patients were entered into the trial (15 males and 11 females; mean age, 59.9 years; age range, 41-81 years). Twenty patients had colorectal carcinoma, and 6 patients had non-small cell lung cancer. A total of 218 infusions of sibrotuzumab were administered during the first 12 weeks of the study, with 24 patients being evaluable. One patient received an additional 96 infusions on continued-use phase for a total of 108 infusions over a 2-year period, and 1 patient received an additional 6 infusions on continued use. There were no objective tumor responses. Only one episode of dose-limiting toxicity was observed. Therefore, a maximum tolerated dose was not reached. Treatment-related adverse events were observed in 6 patients during the infusional monitoring period. Four of the 6 patients, 3 of whom had associated positive serum human antihuman antibody, were removed from the study because of clinical immune responses. Gamma camera images of [131I]sibrotuzumab demonstrated no normal organ uptake of sibrotuzumab, with tumor uptake evident within 24-48 h after infusion. Analysis of pharmacokinetics demonstrated a similar mean terminal t1/2 of 1.4-2.6 days at the 5, 10, and 25 mg/m2 dose levels, and with a longer mean t1/2 of 4.9 days at the 50 mg/m2 dose level. Conclusion: Repeat infusions of the humanized antiFAP antibody sibrotuzumab can be administered safely to patients with advanced FAP-positive cancer.

Original languageEnglish (US)
Pages (from-to)1639-1647
Number of pages9
JournalClinical Cancer Research
Issue number5
StatePublished - May 1 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer'. Together they form a unique fingerprint.

Cite this